Genomic Characterization of


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 05 05 2020
revised: 05 08 2020
accepted: 02 12 2020
pubmed: 10 12 2020
medline: 21 1 2022
entrez: 9 12 2020
Statut: ppublish

Résumé

In contrast to recurrence after initial diagnosis of stage I-III breast cancer [recurrent metastatic breast cancer (rMBC)], Targeted DNA sequencing (OncoPanel) was prospectively performed on either primary or metastatic tumors from 926 patients (212 dnMBC and 714 rMBC). Single-nucleotide variants, copy-number variations, and tumor mutational burden (TMB) in treatment-naïve dnMBC primary tumors were compared with primary tumors in patients who ultimately developed rMBC, and correlated with OS across all dnMBC. When comparing primary tumors by subtype, Genomic differences between treatment-naïve dnMBC and primary tumors of patients who developed rMBC may provide insight into mechanisms underlying metastatic potential and differential therapeutic sensitivity in dnMBC. Alterations associated with poor OS in dnMBC highlight the need for novel approaches to overcome potential intrinsic resistance to current treatments.

Identifiants

pubmed: 33293374
pii: 1078-0432.CCR-20-1720
doi: 10.1158/1078-0432.CCR-20-1720
pmc: PMC7887078
mid: NIHMS1653483
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Comparative Study Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1105-1118

Subventions

Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Sci Rep. 2017 Apr 07;7:45828
pubmed: 28387221
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
Genom Data. 2015 Jun 14;5:272-4
pubmed: 26484266
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
JCO Precis Oncol. 2018;2018:
pubmed: 30035249
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9
pubmed: 17252614
Nat Genet. 2019 Oct;51(10):1450-1458
pubmed: 31570896
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Oncoimmunology. 2018 Jul 30;7(10):e1490854
pubmed: 30386679
Genes Dev. 2017 Jun 1;31(11):1109-1121
pubmed: 28698296
Exp Mol Pathol. 2020 Jun;114:104404
pubmed: 32067942
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Clin Cancer Res. 2020 Nov 15;26(22):5974-5989
pubmed: 32723837
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Breast Cancer Res Treat. 2018 Jan;167(2):579-590
pubmed: 29039120
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815
pubmed: 28522448
Br J Cancer. 2016 Apr 12;114(8):917-28
pubmed: 26954716
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Breast Cancer Res. 2011 Jan 21;13(1):R9
pubmed: 21255398
JAMA Oncol. 2018 Nov 1;4(11):1589-1593
pubmed: 29872864
Oncologist. 2020 Feb;25(2):e214-e222
pubmed: 32043771
Cancer Res. 2016 Jun 1;76(11):3364-75
pubmed: 27197202
JCO Precis Oncol. 2019;3:
pubmed: 31832578
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
Nat Genet. 2016 Feb;48(2):126-133
pubmed: 26656846
Br J Cancer. 2000 Dec;83(12):1688-95
pubmed: 11104567
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
Br J Cancer. 2015 Apr 28;112(9):1445-51
pubmed: 25880008
Ann Oncol. 2019 Jan 1;30(1):115-123
pubmed: 30423024
JCO Precis Oncol. 2019 Nov 15;3:
pubmed: 32923853
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
J Mol Diagn. 2014 Nov;16(6):660-72
pubmed: 25157968
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nat Genet. 2019 Feb;51(2):207-216
pubmed: 30531871

Auteurs

Ana C Garrido-Castro (AC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. agarrido-castro@partners.org.
Harvard Medical School, Boston, Massachusetts.

Liam F Spurr (LF)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Melissa E Hughes (ME)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Yvonne Y Li (YY)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Andrew D Cherniack (AD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Priti Kumari (P)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Maxwell R Lloyd (MR)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Brittany Bychkovsky (B)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Romualdo Barroso-Sousa (R)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Simona Di Lascio (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Esha Jain (E)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Janet Files (J)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Ayesha Mohammed-Abreu (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Max Krevalin (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Colin MacKichan (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

William T Barry (WT)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Hao Guo (H)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Daniel Xia (D)

Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Brigham and Women' Hospital, Boston, Massachusetts.

Ethan Cerami (E)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

Barrett J Rollins (BJ)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Laura E MacConaill (LE)

Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Brigham and Women' Hospital, Boston, Massachusetts.
Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.

Neal I Lindeman (NI)

Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Brigham and Women' Hospital, Boston, Massachusetts.
Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.

Ian E Krop (IE)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Bruce E Johnson (BE)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Nikhil Wagle (N)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Eric P Winer (EP)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Deborah A Dillon (DA)

Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Brigham and Women' Hospital, Boston, Massachusetts.

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH